Form 4: Vita Coco CEO Sells Shares Under 10b5-1 Plan

Vita Coco Company CEO Martin Roper and related trusts sold common stock totaling 21,600 shares in late September 2025 under a pre-arranged trading plan.

Summary

• Martin Roper, Chief Executive Officer and Director of Vita Coco Company, Inc. (COCO), reported sales of common stock.
• A total of 21,600 shares were sold across direct holdings (10,800 shares) and three family trusts (10,800 shares total) indirectly beneficially owned by Mr. Roper.
• These transactions occurred on September 24, 2025, and September 25, 2025.
• All sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• The weighted average sale prices for these transactions ranged from approximately $40.00 to $41.67 per share.
• Following these transactions, Mr. Roper directly holds 318,897 shares of common stock.
• Indirect holdings after the transactions include 253,406 shares via the Christopher G. Roper Exempt Family Trust, 252,515 shares via the Peter S. Roper Exempt Family Trust, 253,531 shares via the Thomas L. Roper Exempt Family Trust, and 61,200 shares via spouse.
• The filing also lists Mr. Roper's beneficial ownership of various non-qualified stock options, totaling 1,049,460 shares, with exercise prices ranging from $10.178 to $32.78 and various vesting schedules.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales by the CEO and related trusts under a pre-arranged 10b5-1 trading plan. Such planned sales are generally considered a neutral event, not indicating positive or negative company performance, and are part of an insider's personal financial management.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates pre-planning and is designed to mitigate concerns about opportunistic insider trading.

Negatives

• Insider selling, even when executed under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence, although this perception is generally less pronounced for planned sales.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It primarily details past insider transactions and current beneficial ownership of securities and options.

Management Comments

• The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan.

Industry Context

This filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape. The sales are specific to the reporting person's personal financial planning under a pre-arranged plan.

Related Party Transactions

• Sales of common stock by the Christopher G. Roper Exempt Family Trust, Peter S. Roper Exempt Family Trust, and Thomas L. Roper Exempt Family Trust, which are indirectly beneficially owned by Martin Roper.
• Indirect beneficial ownership of 61,200 shares by spouse.

Stakeholder Impact

• Shareholders: Potential minor impact on market sentiment due to insider selling, though mitigated by the pre-arranged 10b5-1 plan. No direct financial impact on other shareholders from these specific transactions.

Next Steps

• Future vesting of non-qualified stock options on various dates, with the latest installment beginning March 3, 2026.

Key Dates

Recommendation

The filing details routine insider sales by the CEO and related trusts under a pre-arranged Rule 10b5-1 trading plan. Such planned sales are generally not considered a strong signal for future stock performance and do not typically warrant a change in investment recommendation. A 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to alter a fundamental investment thesis.

Keywords

Vita Coco, COCO, Martin Roper, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Beneficial Ownership